Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Face NPPA fine for overcharging on anti-asthma drug
Entering Iran may lead to trouble for those having significant presence in the US market.
While several export-oriented Indian companies such as Cipla and Reliance Industries Ltd (RIL) are rejoicing at the prospects of the rupee falling further, others that are importing raw materials such as coal and oil might see a big hole in their bottom line.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Yusuf Hamied, Anji Reddy and Parvinder Singh are the real pioneers of the Indian pharmaceutical industry.
The health ministry on Saturday recommended the use of antiviral drug remdesivir in moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease and not on critically ill patients.
Regulator says fee would enable it to quicken approval process.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' queries on a weekly basis.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
To some -- especially western drug companies -- he is a 'pirate'. To others, mostly those in developing countries, he is an unparalleled hero. Either way, Yusuf Hamied, 75, is perhaps the most talked about man in pharmaceutical circles in the last decade.
This move could cost $299 million a year for Indian pharma players.
The western world had largely considered India to be a production hub, and also, a good potential geography for clinical trials, and a big market. But in Covid-19 research, Indian companies and government researchers are also researching new drug candidates and potential vaccines, says Prosenjit Datta.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
The antiviral drug may cost around Rs 55,000 for an 11-dose course, or Rs 5,000 per injection -- much less than the price of imports from Bangladesh, reports Sohini Das.
Sun Pharma stock has appreciated at 35% a year for 20 years
European countries are trying to woo back the Indian customers they had lost following seizure of drug consignments by Customs authorities of several European Union members.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The National Pharmaceutical Pricing Authority, which regulates the prices of medicines, has identified around 70 anti-cancer drugs, including anti-breast cancer medication Letrozole and anti-blood cancer drug Imatinib, for detailed price analysis.
Aggressive smaller players are serving a bitter pill to the big boys in the pharmaceutical sector.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
The rupee's appreciation of 6.4 per cent against the dollar and 12 per cent against the euro is likely to hurt the first-quarter performance of the pharmaceutical sector, indicate a results' preview by broking houses.
Pharmaceutical patents are just over a fourth of all patents granted in the country, but domestic drug makers account for almost all post-grant patent opposition filed, official data reveals.
As many as 14 Indian families have made it to the inaugural list of Forbes' 50 richest families in Asia.
Impact of the slowdown is most visible among promoter/owner-CEOs
As record stock market rally continues, the value of shares directly owned by next-generation business leaders at 20 major corporate houses has soared over 18 per cent to Rs 17,000 crore.
Indian drug companies have cornered an overwhelming majority of drug approvals under the US President's Emergency Plan for AIDS Relief.
An Indian pharmaceutical company is gearing up to sell a cheap version of the leading patented antiviral flu drug Tamiflu to emerging economies, in a move that will pitch intellectual property rights against affordable access to medicines.
India plans to increase stockpiles of the anti-influenza drug Tamiflu or its generic version by 10-fold, from one million to 10 million currently, Bloomberg reported, citing Vineet Choudhary, joint secretary, Ministry of Health.
The voluntary move comes a little more than a year after the Central Drugs Standard Control Organisation, the central authority that approves new drugs for marketing, had asked the drug makers to withdraw the 'combination drugs' as they are 'unnecessary' and may pose health hazards. The Drugs Controller General of India had banned 294 combination drugs sold under nearly 1,053 brand names from the market in June 2007.
ABRPL is working on developing drugs for anaemia, cancer and arthritis, said Bruce Murdoch, chief business officer, Avesthagen. "We are targeting high-end products that are going off-patent and are not working on popular soon-to-be off-patent biotech molecules. We should be able to bring a couple of molecules into the commercialisation stage next year," he said.
The country had the third-largest number of people living with disease.
Ranbaxy, Cipla and other Indian drug makers are helping US retailer Wal-Mart sell drugs at low cost and boost revenue.
Making the things worse, those hitting their record low share prices included big names like Reliance Power, Cipla, Ranbaxy, Ambuja Cement, Hindalco, Indian Hotels, Jaiprakash Associates, Jet Airways, Suzlon Energy and Idea Cellular. Realty majors DLF Ltd, Unitech, Parsvnath, Sobha Developers, Omaxe and Puravankara also plunged to their all-time lows.
Voveran, Novartis India's flagship pain killer medicine, has become the largest selling domestic drug with sales of more than Rs 11 crore (Rs 110 million) in March 2008, displacing Pfizer India's cough and cold syrup Corex, which had sales of Rs 10 crore (Rs 100 million). Cipla, on the other hand, maintained its leadership position as the largest domestic pharmaceutical company edging out Ranbaxy Laboratories with a market share of 5.24 per cent.
Justice Rajiv Sahai Endlaw allowed 454 petitions moved by various pharma and healthcare majors, like Pfizer, Glenmark, Procter and Gamble and Cipla, challenging the government's March 10 notification banning the FDCs, saying the decision was taken by the Centre without following procedure prescribed in the Drugs and Cosmetics Act.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances